Ascendis Pharma A/S (ASND)
| Market Cap | 6.77B |
| Revenue (ttm) | 33.18M |
| Net Income (ttm) | -481.83M |
| Shares Out | 55.83M |
| EPS (ttm) | -8.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,017 |
| Open | 119.22 |
| Previous Close | 119.45 |
| Day's Range | 116.48 - 120.25 |
| 52-Week Range | 61.58 - 144.25 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 156.83 (+34.0%) |
| Earnings Date | Nov 2, 2022 |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic... [Read more]
Financial Performance
In 2021, ASND's revenue was 7.78 million, an increase of 11.87% compared to the previous year's 6.95 million. Losses were -383.58 million, -8.44% less than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for ASND stock is "Buy." The 12-month stock price forecast is 156.83, which is an increase of 33.96% from the latest price.
News
Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
- The program will allow physicians to request access to TransCon PTH, the company's investigational parathyroid hormone replacement therapy, for eligible patients in the United States
Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx Conferenc...
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adu...
TransCon PTH is designed to be the first parathyroid hormone replacement therapy, addressing an area of major unmet medical need TransCon PTH is designed to be the first parathyroid hormone replacement ...
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma...
- Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and convenient treatment
Dose Escalation Data from transcendIT-101, Ascendis Pharma's Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients ...
- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy
Ascendis Pharma Reports Third Quarter 2022 Financial Results
- SKYTROFA ® U.S. revenue more than doubled quarter-to-quarter again, reaching €12.3 million in the third quarter
FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
- PDUFA target action date is April 30, 2023
Does Ascendis Pharma AS (ASND) Have the Potential to Rally 35% as Wall Street Analysts Expect?
The consensus price target hints at a 34.6% upside potential for Ascendis Pharma AS (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...
Frazier Life Sciences Adds Experienced Biopharmaceutical Executive to Team
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive. Mr. Mi...
Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Tri...
- TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab
Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism
• TransCon PTH could , if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated 70,000-90,...
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at ...
Why Ascendis Pharma Stock Is Sinking Today
Investors are reacting negatively to the company's Q1 update.
Ascendis Pharma A/S Reports First Quarter 2022 Financial Results
COPENHAGEN, Denmark, May 11, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
Why Ascendis Pharma (ASND) Might Surprise This Earnings Season
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference
COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference. Company e...
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
New data highlights include:
Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering
COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidate...
Ascendis Pharma Announces Proposed Convertible Senior Notes Offering
COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidate...
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary an...
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Investor...
Should You Buy Ascendis Pharma (ASND) Ahead of Earnings?
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update
- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter
Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2
COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:3...